Hofseth BioCare ASA

HBC.OL

HBC.OLHofseth BioCare ASA NO flag

Oslo Stock Exchange

3.00

NOK

-0.03

(-0.99%)

-0.33EPS

-9.09P/E

1.19BMarket Cap

May 09Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

NO0010598683

Return %

Stock

S&P500

15.38

24.74

-50.00

37.69

-69.33

82.03

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.03	0.45	0.87	0.22	0.52	0.14	0.51	0.23	0.22	0.21	0.24	0.32	0.49	0.58
Basic EPS, GAAP	-0.45	-1.29	-0.72	-0.73	-0.95	-1.01	-0.07	-0.33	-0.29	-0.31	-0.35	-0.37	-0.27	-0.32
Free Cash Flow per Basic Share	-1.15	-1.14	-1.46	-0.78	-0.04	-0.75	-0.17	-0.15	-0.17	-0.35	-0.28	-0.17	-0.03	-0.12
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1.34	0.81	0.86	0.87	0.31	0.37	0.16	0.33	0.38	0.06	0.01	0.01	0.01	0.01
Tangible Book Value per Share	1.91	0.15	0.51	0.58	0.09	0.26	0.08	0.27	0.3	0.66	0.24	0.23	-0.04	0.14
Basic Weighted Avg Shares	43	57	73	91	106	146	234	259	307	334	358	375	395	411
Sales/Revenue/Turnover	1	26	63	20	55	20	118	61	68	69	88	120	195	240
Operating Margin (%)	-2,055.62	-223.12	-77.77	-325.82	-171.51	-719.93	-10.11	-129.2	-118.55	-133.18	-135.32	-106.78	-64.74	-52.45
Depreciation Expense	2	8	13	18	19	26	22	22	27	27	29	30	36	39
Net Income, GAAP	-19	-74	-52	-67	-100	-147	-16	-85	-89	-102	-126	-137	-107	-133
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-1,609.13	-283.91	-82.84	-338.5	-181.72	-729.81	-13.91	-139.56	-131.62	-147.42	-144.34	-114.06	-54.74	-55.65
Working Capital	25	-64	-16	14	13	-23	-8	29	66	165	19	4	-121	-47
LT Debt	22	- -	36	45	86	46	44	30	104	89	125	91	97	90
Total Equity	121	48	62	79	33	54	37	86	118	264	140	148	41	103
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	-44.29	-142.15	-95.49	-94.11	-177.67	-337.36	-35.83	-136.21	-87.32	-149.41	-1,117.51	-3,649.59	-2,700.15	-3,310.44

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	62.42%	27.91%	61.79%
Net Income, GAAP	48.08%	5.97%	-22.35%
Free Cash Flow	257.11%	5.39%	-82.05%
Total Cash Common Dividend	- -	- -	- -
Total Equity	18.17%	9.46%	-72.21%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Jon Olav Odegard
Full Time Employees: 69
Sector: Healthcare
Industry: Biotechnology
Address: Kipervikgata 13 Ålesund Norway 6003
IPO Date: Dec 2, 2011
Website: hofsethbiocare.no
Similar Companies: Hybrigenics SA (ALHYG.PA)
HLB Therapeutics Co.,Ltd. (115450.KQ)
Lexaria Bioscience Corp. (LEXXW)
Ember Therapeutics, Inc. (EMBT)
Stemcell Holdings, Inc. (STMM)
Vaxcyte, Inc. (PCVX)
Business: Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Year	Q1	Q2	Q3	Q4	FY
2022	-0.1	-0.08	-0.09	- -	-0.37
2023	-0.1	0.01	-0.06	- -	-0.27
2024	-0.07	-0.04	-0.09	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	31	26	30	34	120
2023	45	53	50	47	195
2024	52	72	68	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	- -	- -	- -	- -	- -
2023	- -	- -	- -	- -	- -
2024	- -	- -	- -	- -	- -

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.03	0.45	0.87	0.22	0.52	0.14	0.51	0.23	0.22	0.21	0.24	0.32	0.49	0.58
Basic EPS, GAAP	-0.45	-1.29	-0.72	-0.73	-0.95	-1.01	-0.07	-0.33	-0.29	-0.31	-0.35	-0.37	-0.27	-0.32
Free Cash Flow per Basic Share	-1.15	-1.14	-1.46	-0.78	-0.04	-0.75	-0.17	-0.15	-0.17	-0.35	-0.28	-0.17	-0.03	-0.12
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1.34	0.81	0.86	0.87	0.31	0.37	0.16	0.33	0.38	0.06	0.01	0.01	0.01	0.01
Tangible Book Value per Share	1.91	0.15	0.51	0.58	0.09	0.26	0.08	0.27	0.3	0.66	0.24	0.23	-0.04	0.14
Basic Weighted Avg Shares	43	57	73	91	106	146	234	259	307	334	358	375	395	411
Sales/Revenue/Turnover	1	26	63	20	55	20	118	61	68	69	88	120	195	240
Operating Margin (%)	-2,055.62	-223.12	-77.77	-325.82	-171.51	-719.93	-10.11	-129.2	-118.55	-133.18	-135.32	-106.78	-64.74	-52.45
Depreciation Expense	2	8	13	18	19	26	22	22	27	27	29	30	36	39
Net Income, GAAP	-19	-74	-52	-67	-100	-147	-16	-85	-89	-102	-126	-137	-107	-133
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-1,609.13	-283.91	-82.84	-338.5	-181.72	-729.81	-13.91	-139.56	-131.62	-147.42	-144.34	-114.06	-54.74	-55.65
Working Capital	25	-64	-16	14	13	-23	-8	29	66	165	19	4	-121	-47
LT Debt	22	- -	36	45	86	46	44	30	104	89	125	91	97	90
Total Equity	121	48	62	79	33	54	37	86	118	264	140	148	41	103
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	-44.29	-142.15	-95.49	-94.11	-177.67	-337.36	-35.83	-136.21	-87.32	-149.41	-1,117.51	-3,649.59	-2,700.15	-3,310.44

	Mar'24	Jun'24	Sep'24
ST Debt	67	77	96
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	395	395	395
Market Capitalization	832	827	711

	Mar'24	Jun'24	Sep'24
Total Current Assets	139	136	125
Accounts Receivable, Net	23	27	29
Cash, Cash Equivalents & STI	22	25	23
Inventories	84	72	63
Total Current Liabilities	139	156	173
Payables & Accruals	- -	- -	- -
ST Debt	67	77	96
Deferred Revenue	- -	- -	- -

Hofseth BioCare ASA

Growth Rates

(avg. rate of change)

Company Description

Quarterly Earnings Per Share

Year

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Capital Structure

Working Capital